Linfoma primitivo del mediastino

Bibliografia

1. Overview sulla diagnosi, sulla presentazione clinica e sulla storia del trattamento

-Broccoli A, Zinzani PL. The unique biology and treatment of primary mediastinal B-cell lymphoma. Best Pract Res Clin Haematol, 2018; 31: 241-250.

2. Aspetti biologici della malattia

– Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, 2010; 116: 3268-3277.

-Shi M, Roemer MGM, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol, 2014; 38: 1715-1723.

-Camus V, Viailly PJ, Drieux F, et al. High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma. Blood Adv, 2023; 7: 7331-7345.

3. Terapia di prima linea

-Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma, 2009; 9: 381-385.

-Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med, 2013; 368: 1408-1416.

-Giulino-Roth L, O’Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol, 2017; 179: 739-747.

-Casadei B, Argnani L, Morigi A, et al. Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients. Ann Hematol, 2021; 100: 2261-2268.

-Martelli M, Zucca E, Botto B, et al. Impact of different induction regimens on the outcome of primary mediastinal B cell lymphoma in the prospective IELSG37 trial. Hematol Oncol (16 ICML Meeting abstracts), 2021; 39: 049a.

4. Il significato della radioterapia di consolidamento in funzione della rivalutazione PET post-prima linea

-Zinzani PL, Broccoli A, Casadei B, et al. The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. Hematol Oncol, 2015; 33(4):145-50.

-Pinnix CC, Ng AK, Dabaja BS, et al. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv, 2018; 2: 1334-1343.

-Hayden AR, Tonseth P, Lee DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood, 2020; 136: 2803-2811.

-Davies AJ, Zucca E, Ceriani L, et al. A randomized trial of observation versus radiotherapy in primary mediastinal B-cell lymphoma patients with complete metabolic response after standard immunochemotherapy. Hematol Oncol (17 ICML meeting abstracts), 2023; 41(S2): 019a.

5. Terapia della malattia in ricaduta e refrattaria: ruolo dei checkpoint inibitori, da soli e in combinazione, e della terapia con CART

-Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood, 2023; 142: 141-145.

-Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up. Blood Adv, 2023; 7: 5272-5280.

-Crombie JL, Nastoupil LJ, Redd R, et al. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021; 5: 3563-3567.

-Chiappella A, Casadei B, Chiusolo P, et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia, 2024; 38: 1107-1114.